Peptide peddlers cheer as RFK Jr. unilaterally grants access, overruling FDA
RFK Jr. unilaterally enacted an enforcement discretion policy that permits compounding pharmacies to produce six peptides without FDA restriction, overriding the agency's 2023 decision to remove them from approved compounding drug lists due to insufficient efficacy evidence and safety concerns. The rule effectively allows market distribution without changing the regulatory classification. Several MAHA-aligned figures and Kennedy allies reportedly sell these peptides commercially.
Key points
- RFK Jr. issued enforcement discretion rule enabling peptide sales via compounding pharmacies
- FDA scientists maintain safety and efficacy evidence remains insufficient
- Rule bypasses formal FDA action reversal, instead halting enforcement
- Peptides linked to Kennedy allies and Make America Health Again movement
Summary and key points written by AI from the headline and a short excerpt, so they can be incomplete or wrong. Ars Technica did the reporting; read the original for the full story.
Read the full story at Ars Technica
